Genomic characterization of functional high-risk multiple myeloma patients
Abstract Multiple myeloma (MM) patients with suboptimal response to induction therapy or early relapse, classified as the functional high-risk (FHR) patients, have been shown to have poor outcomes. We evaluated newly-diagnosed MM patients in the CoMMpass dataset and divided them into three groups: g...
Main Authors: | Cinnie Yentia Soekojo, Tae-Hoon Chung, Muhammad Shaheryar Furqan, Wee Joo Chng |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2022-01-01
|
Series: | Blood Cancer Journal |
Online Access: | https://doi.org/10.1038/s41408-021-00576-3 |
Similar Items
-
Immunotherapy in Multiple Myeloma
by: Cinnie Yentia Soekojo, et al.
Published: (2020-03-01) -
Fibrillary Glomerulonephritis and Monoclonal Gammopathy: Potential Diagnostic Challenges
by: Yi Da, et al.
Published: (2022-05-01) -
Immunoglobulin M Monoclonal Gammopathies of Clinical Significance
by: Louis-Pierre Girard, et al.
Published: (2022-06-01) -
Stem-cell transplantation in multiple myeloma: how far have we come?
by: Cinnie Y. Soekojo, et al.
Published: (2019-11-01) -
Myeloma-specific superenhancers affect genes of biological and clinical relevance in myeloma
by: Yunlu Jia, et al.
Published: (2021-02-01)